Wyeth Antibiotic Tygacil Approved For Broad-Spectrum, Early Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Tigecycline, a first-in-class antibiotic, receives approval June 15 after a six-month priority review. Wyeth is highlighting Tygacil's broad-spectrum efficacy and potential as an empiric monotherapy. The application was based on two trials in complicated skin and skin structure infections and two trials in complicated intra-abdominal infections.
You may also be interested in...
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.
J&J Submits Ceftobiprole NDA
Novel cephalosporin would be used to treat complicated skin and skin structure infections, including diabetic foot infections.